Olive Leaf Extracts in the Control of Hypertension

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

December 30, 2023

Primary Completion Date

November 22, 2024

Study Completion Date

December 30, 2025

Conditions
Hypertension
Interventions
DRUG

atherolive-drug

The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.

DRUG

Placebo Atherolive

The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.

Trial Locations (1)

Unknown

RECRUITING

University Hospital Fattouma Bourguiba Monastir, Monastir

All Listed Sponsors
lead

University of Monastir

OTHER